Last reviewed · How we verify
KLA578-1 for injection
KLA578-1 for injection is a Small molecule drug developed by Sichuan Kelun Pharmaceutical Co., Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | KLA578-1 for injection |
|---|---|
| Sponsor | Sichuan Kelun Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KLA578-1 for injection CI brief — competitive landscape report
- KLA578-1 for injection updates RSS · CI watch RSS
- Sichuan Kelun Pharmaceutical Co., Ltd portfolio CI
Frequently asked questions about KLA578-1 for injection
What is KLA578-1 for injection?
KLA578-1 for injection is a Small molecule drug developed by Sichuan Kelun Pharmaceutical Co., Ltd.
Who makes KLA578-1 for injection?
KLA578-1 for injection is developed by Sichuan Kelun Pharmaceutical Co., Ltd (see full Sichuan Kelun Pharmaceutical Co., Ltd pipeline at /company/sichuan-kelun-pharmaceutical-co-ltd).
What development phase is KLA578-1 for injection in?
KLA578-1 for injection is in Phase 1.